Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-F1202 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ALN-F1202 | EXPERIMENTAL | Randomized as described in the protocol Escalating Cohorts including Optional Cohorts |
| Placebo | EXPERIMENTAL | Randomized as described in the protocol |
| Name | Type | Description |
|---|---|---|
| ALN-F1202 | DRUG | Administered per the protocol |
| Matching Placebo | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1. Has a body mass index between 18 and 32 kg/m2, inclusive 2. Is judged by the investigator to be in good health based on medical history, physical examination, vital sign measurements, and electrocardiograms (ECGs) performed at screening and/or prior to administration of i...
ALN-F1202 is an investigational small molecule being developed by Regeneron Pharmaceuticals, Inc. (REGN). It is currently in Phase 1 clinical development for use in healthy volunteers. The drug is being studied for safety and tolerability in a clinical trial setting.
ALN-F1202 is being studied for use in healthy volunteers as part of a Phase 1 clinical trial. The trial is designed to evaluate the safety and tolerability of the drug in adults. It is not yet approved for any medical condition and remains in early-stage clinical development.
ALN-F1202 is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol REGN. The company is conducting a Phase 1 clinical trial to assess the drug's safety and tolerability in healthy adult volunteers.
ALN-F1202 is in Phase 1 clinical development. The drug is being evaluated in a Phase 1 safety and tolerability study involving healthy adults. It is an investigational drug and has not been approved by regulatory authorities for any use.
ALN-F1202 is being studied in one active Phase 1 clinical trial, identified as NCT06669234. This trial is titled 'Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults' and is being conducted in Belgium. The study is randomized, double-blind, and controlled, with an enrollment of 56 participants.
ALN-F1202 is the primary name for this investigational drug. No alternative names have been associated with it in the available clinical trial information. It is being developed solely under this name by Regeneron Pharmaceuticals, Inc.